These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 37334368)

  • 1. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
    Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
    Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APLNR inhibited nasopharyngeal carcinoma growth and immune escape by downregulating PD-L1.
    Liu Y; Li N; Guo Y; Zhou Q; Yang Y; Lu J; Tian Z; Zhou J; Yan S; Li X; Shi L; Jiang S; Ge J; Feng R; Huang D; Zeng Z; Fan S; Xiong W; Li G; Zhang W
    Int Immunopharmacol; 2024 Aug; 137():112523. PubMed ID: 38909500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
    Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
    Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
    Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
    Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acidosis-mediated increase in IFN-γ-induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors.
    Knopf P; Stowbur D; Hoffmann SHL; Hermann N; Maurer A; Bucher V; Poxleitner M; Tako B; Sonanini D; Krishnamachary B; Sinharay S; Fehrenbacher B; Gonzalez-Menendez I; Reckmann F; Bomze D; Flatz L; Kramer D; Schaller M; Forchhammer S; Bhujwalla ZM; Quintanilla-Martinez L; Schulze-Osthoff K; Pagel MD; Fransen MF; Röcken M; Martins AF; Pichler BJ; Ghoreschi K; Kneilling M
    Mol Cancer; 2023 Dec; 22(1):207. PubMed ID: 38102680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chrysin inhibits hepatocellular carcinoma progression through suppressing programmed death ligand 1 expression.
    Rong W; Wan N; Zheng X; Shi G; Jiang C; Pan K; Gao M; Yin Z; Gao ZJ; Zhang J
    Phytomedicine; 2022 Jan; 95():153867. PubMed ID: 34923234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X; Gao L; Wang B; Hu J; Yu Y; Gu B; Xiang L; Li X; Li H; Zhang T; Wang Y; Ma C; Dong J; Lu J; Lucas A; Chen H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
    Patra T; Cunningham DM; Meyer K; Toth K; Ray RB; Heczey A; Ray R
    Mol Ther; 2023 Mar; 31(3):715-728. PubMed ID: 36609146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
    Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
    Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
    Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
    J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.
    Chen YC; He XL; Qi L; Shi W; Yuan LW; Huang MY; Xu YL; Chen X; Gu L; Zhang LL; Lu JJ
    Biochem Pharmacol; 2022 Mar; 197():114940. PubMed ID: 35120895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
    Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
    Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis.
    Li T; Huang HY; Qian B; Wang WH; Yuan Q; Zhang HY; He J; Ni KJ; Wang P; Zhao ZY; He JL; Fu SW; Xu L; Lin YC; Lin ZN
    Free Radic Biol Med; 2024 Feb; 212():360-374. PubMed ID: 38171407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.